247 related articles for article (PubMed ID: 29097143)
1. Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.
Taya M; Hammes SR
Steroids; 2018 May; 133():102-107. PubMed ID: 29097143
[TBL] [Abstract][Full Text] [Related]
2. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.
Rose AA; Annis MG; Dong Z; Pepin F; Hallett M; Park M; Siegel PM
PLoS One; 2010 Aug; 5(8):e12093. PubMed ID: 20711474
[TBL] [Abstract][Full Text] [Related]
3. GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.
Maric G; Annis MG; Dong Z; Rose AA; Ng S; Perkins D; MacDonald PA; Ouellet V; Russo C; Siegel PM
Oncogene; 2015 Oct; 34(43):5494-504. PubMed ID: 25772243
[TBL] [Abstract][Full Text] [Related]
4. GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity.
Fiorentini C; Bodei S; Bedussi F; Fragni M; Bonini SA; Simeone C; Zani D; Berruti A; Missale C; Memo M; Spano P; Sigala S
Exp Cell Res; 2014 Apr; 323(1):100-111. PubMed ID: 24589892
[TBL] [Abstract][Full Text] [Related]
5. The laminin-derived peptide C16 regulates GPNMB expression and function in breast cancer.
Smuczek B; Santos ES; Siqueira AS; Pinheiro JJV; Freitas VM; Jaeger RG
Exp Cell Res; 2017 Sep; 358(2):323-334. PubMed ID: 28689015
[TBL] [Abstract][Full Text] [Related]
6. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
[TBL] [Abstract][Full Text] [Related]
7. Osteoactivin (GPNMB) ectodomain protein promotes growth and invasive behavior of human lung cancer cells.
Oyewumi MO; Manickavasagam D; Novak K; Wehrung D; Paulic N; Moussa FM; Sondag GR; Safadi FF
Oncotarget; 2016 Mar; 7(12):13932-44. PubMed ID: 26883195
[TBL] [Abstract][Full Text] [Related]
8. Glycoprotein nonmetastatic melanoma protein B (GPNMB) promotes the progression of brain glioblastoma via Na
Ono Y; Chiba S; Yano H; Nakayama N; Saio M; Tsuruma K; Shimazawa M; Iwama T; Hara H
Biochem Biophys Res Commun; 2016 Dec; 481(1-2):7-12. PubMed ID: 27836549
[TBL] [Abstract][Full Text] [Related]
9. Glycoprotein non-metastatic melanoma protein B functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation.
Wang C; Okita Y; Zheng L; Shinkai Y; Manevich L; Chin JM; Kimura T; Suzuki H; Kumagai Y; Kato M
Cancer Sci; 2021 Oct; 112(10):4187-4197. PubMed ID: 34327762
[TBL] [Abstract][Full Text] [Related]
10. The potential role of the glycoprotein osteoactivin/glycoprotein nonmetastatic melanoma protein B in pancreatic cancer.
Torres C; Linares A; Alejandre MJ; Palomino-Morales R; Martin M; Delgado JR; Martinez J; Perales S
Pancreas; 2015 Mar; 44(2):302-10. PubMed ID: 25426614
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Chang PL; Juang HH
Prostate; 2012 Sep; 72(13):1431-42. PubMed ID: 22290289
[TBL] [Abstract][Full Text] [Related]
12. Glycoprotein non-metastatic melanoma protein B as a predictive prognostic factor in clear-cell renal cell carcinoma following radical nephrectomy.
Qin C; Liu Z; Yuan Y; Zhang X; Li H; Zhang C; Xu T; Wang X
Mol Med Rep; 2014 Mar; 9(3):851-6. PubMed ID: 24425288
[TBL] [Abstract][Full Text] [Related]
13. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
[TBL] [Abstract][Full Text] [Related]
14. Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions.
Zhuo H; Zhou L
Pharmazie; 2016 Oct; 71(10):555-561. PubMed ID: 29441921
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
16. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
Rose AAN; Biondini M; Curiel R; Siegel PM
Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082
[TBL] [Abstract][Full Text] [Related]
17. GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway.
Jin R; Jin YY; Tang YL; Yang HJ; Zhou XQ; Lei Z
Oncol Rep; 2018 Jun; 39(6):3034-3040. PubMed ID: 29620278
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.
Kanematsu M; Futamura M; Takata M; Gaowa S; Yamada A; Morimitsu K; Morikawa A; Mori R; Hara H; Yoshida K
Cancer Med; 2015 Sep; 4(9):1344-55. PubMed ID: 26077887
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme.
Kuan CT; Wakiya K; Dowell JM; Herndon JE; Reardon DA; Graner MW; Riggins GJ; Wikstrand CJ; Bigner DD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1970-82. PubMed ID: 16609006
[TBL] [Abstract][Full Text] [Related]
20. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
